SCHEMBL144597

SCHEMBL144597

NCCCOC(=O)/C=C/c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B10 O60218 7/20 0.65
AKR1B1 P15121 7/20 0.65
LMNA P02545 3/20 0.59
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAOB P27338 1/20 0.55
APP P05067 2/20 0.55
ALDH1A1 P00352 2/20 0.55
CA12 O43570 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
ALOX5 P09917 2/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 1/20 0.48
GMNN O75496 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144598 1.00 AKR1B10 (0.65) AKR1B10AKR1B1LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL143255 0.98 AKR1B10 (0.63) AKR1B10AKR1B1LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL143254 0.98 AKR1B10 (0.63) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL7997845 0.95 AKR1B10 (0.63) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL7997849 0.95 AKR1B10 (0.63) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL8009699 0.94 AKR1B10 (0.61) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL8007280 0.94 AKR1B10 (0.61) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL8008069 0.94 AKR1B10 (0.61) AKR1B10AKR1B1LMNAMEN1KMT2A
SCHEMBL7997837 0.94 AKR1B10 (0.61) AKR1B10AKR1B1LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL1746110 0.94 AKR1B10 (0.61) AKR1B10AKR1B1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779593-B2 Agent for improving ocular subjective symptoms and method thereof SEIKAGAKU CORPORATION (JP) 2023-10-10 US claimed
US-20220105125-A1 AGENT FOR IMPROVING OCULAR SUBJECTIVE SYMPTOMS AND METHOD THEREOF SEIKAGAKU CORPORATION (JP) 2022-04-07 US claimed
US-20210380727-A1 NOVEL PHOTOCROSSLINKABLE ALGINIC ACID DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2021-12-09 US claimed
EP-3760647-A1 NOVEL PHOTOCROSSLINKABLE ALGINIC ACID DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2021-01-06 EP claimed
CN-111918881-A Novel photocrosslinkable alginic acid derivative 持田制药株式会社 2020-11-10 CN claimed
US-9301972-B2 Hyaluronic acid derivatives SEIKAGAKU CORPORATION (JP) 2016-04-05 US claimed
US-20150094280-A1 PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS SEIKAGAKU CORPORATION (JP) 2015-04-02 US claimed
US-8536317-B2 Crosslinked polysaccharide sponge SEIKAGAKU CORPORATION (JP) 2013-09-17 US claimed
US-8389713-B2 Polysaccharide pseudo-sponge SEIKAGAKU CORPORATION (JP) 2013-03-05 US claimed
US-20120055780-A1 POLYSACCHARIDE PSEUDO-SPONGE SEIKAGAKU CORPORATION (JP) 2012-03-08 US claimed
US-20110098455-A1 Crosslinked polysaccharide sponge SEIKAGAKU CORPORATION (JP) 2011-04-28 US claimed
US-7893225-B2 Formed by freezing photoreactive polysaccharide (hyaluronic acids) solution, then irradiating to crosslink; requires no removal of solvent SEIKAGAKU CORPORATION (JP) 2011-02-22 US claimed
US-11779593-B2 Agent for improving ocular subjective symptoms and method thereof SEIKAGAKU CORPORATION (JP) 2023-10-10 US disclosed
US-20220370630-A1 TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER SEIKAGAKU CORPORATION (JP) 2022-11-24 US disclosed
US-11472891-B2 Photocrosslinkable alginic acid derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2022-10-18 US disclosed
CN-111918881-B Novel photocrosslinkable alginic acid derivative 持田制药株式会社 2022-08-12 CN disclosed
US-6025444-A HYALURONIC ACID POLYSACCHARIDE DERIVATIVE; PHOTODIMERIZABLE, CROSSLINKABLE SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) 2000-02-15 US disclosed
CN-1037511-C Therapeutic agents BOOTS CO PLC (GB) 1998-02-25 CN disclosed
EP-0713859-A2 Cinnamic acid derivatives, photocrosslinkable cinnamic acid-polymer derivative and crosslinked cinnamic acid polymer derivatives SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) 1996-05-29 EP disclosed
CN-1096781-A The therapeutical agent that contains 1-(aralkyl-aminoalkyl) imidazolium compounds BOOTS CO PLC (GB) 1994-12-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370630-A1 TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER PIGS, MMP7, CD44 AKR1B10 1825/4885AKR1B1 1931/4885LMNA 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.